Search results
Getting In on This “Macro-Trend”
InvestorPlace via Yahoo Finance· 6 days agoHello, Reader. Wall Street has sold investors on the idea that they should start with “micro” analysis. That’s the idea that they should make investment decisions by comparing things like price ...
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
BioPharma Dive via Yahoo Finance· 5 days agoAmong the pipeline changes is a decision by Takeda to terminate studies in blood cancer of TAK-007,...
Inflation and consumer spending updates ahead: What to know this week
Yahoo Finance· 1 day agoA crucial reading of inflation faces investors in the week ahead after a string of disappointing...
Ajax, aiming for a better JAK drug, raises $95M to begin first tests
BioPharma Dive via Yahoo Finance· 2 days agoGoldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be...
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields -...
Benzinga· 4 days agoLoading... Loading... During times of turbulence and uncertainty in the markets, many investors turn...
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
Motley Fool via Yahoo Finance· 6 days agoAfter steadily raising its payout by 163% over the past 15 years, Pfizer (NYSE: PFE) continues to be...
This company has been the biggest drag on the S&P 500’s results this quarter
Market Watch· 2 days agoHigher prices for groceries, which make up a majority of Walmart’s sales, have helped, even as...
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
BioPharma Dive via Yahoo Finance· 4 days agoInterim data surpassed expectations, iTeos said. Elsewhere, Acelyrin revealed chief executive...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 2 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Investor's Business Daily· 5 days agoNeurocrine Biosciences is making good on its promise to diversify from its blockbuster drug...
